Effect of Acute and Chronic Vitamin D Administration on Systemic Renin Angiotensin System in Essential Hypertensives and Controls

Overview

Journal J Endocrinol Invest

Publisher Springer

Specialty Endocrinology

Date 2013 May 7

PMID 23645099

Citations 9

Authors

G Bernini

D Carrara

A Bacca

V Carli

A Virdis

I Rugani

E Duranti

L Ghiadoni

M Bernini

S Taddei

Affiliations

Soon will be listed here.

Abstract

Aim: To investigate the systemic renin-angiotensin system (RAS) in essential hypertensives (EH) and controls (C) after short- and long-term vitamin D receptor activation.

Design: Ten consecutive EH (under controlled low-salt diet) and 10 C underwent calcitriol administration (0.25 μg bid) for 1 week (Group A). Eighteen consecutive EH under angiotensin II receptor antagonist therapy received a single oral dose of 300,000 IU of cholecalciferol and were followed up for 8 weeks (Group B).

Methods: In basal conditions and at the end of the study (1 week in Group A and 8 weeks in Group B), plasma renin activity (PRA), plasma active renin, aldosterone, and angiotensin II were evaluated, as well as blood pressure, plasma 25-hydroxyvitamin D [25(OH)D], 1,25-dihydroxyvitamin D [1,25(OH)2D], and PTH.

Results: In Group A, plasma 25(OH)D levels in EH and C were below the normal range, although lower levels were found in the former. No association between basal plasma 25(OH)D or 1,25(OH)2D levels and blood pressure values or RAS components was observed either in the whole group or in the two subgroups. Calcitriol administration did not affect any RAS parameter either in EH or in C. In Group B, cholecalciferol significantly increased 25(OH)D and 1,25(OH)2D levels without interfering with the angiotensin II receptor antagonist-induced increase in RAS components. No correlation was found between plasma 25(OH)D or 1,25(OH)2D levels and blood pressure values or RAS parameters before and after cholecalciferol administration.

Conclusions: The present data suggest that, in our experimental conditions, vitamin D receptor activation is unable to influence systemic RAS activity.

Citing Articles

Vitamin D Determinants, Status, and Antioxidant/Anti-inflammatory-Related Effects in Cardiovascular Risk and Disease: Not the Last Word in the Controversy.

Della Nera G, Sabatino L, Gaggini M, Gorini F, Vassalle C Antioxidants (Basel). 2023; 12(4).

PMID: 37107323 PMC: 10135791. DOI: 10.3390/antiox12040948.

Latest Knowledge on the Role of Vitamin D in Hypertension.

Jensen N, Wehland M, Wise P, Grimm D Int J Mol Sci. 2023; 24(5).

PMID: 36902110 PMC: 10003079. DOI: 10.3390/ijms24054679.

The Association between Vitamin D Levels and Thrombus Burden in Patients with ST-Elevation Myocardial Infarction.

Saylik F, Selcuk M, Akbulut T, Cinar T J Tehran Heart Cent. 2022; 17(2):48-55.

PMID: 36567933 PMC: 9748235. DOI: 10.18502/jthc.v17i2.9835.

Is Vitamin D Supplementation an Effective Treatment for Hypertension?.

Chen S, Gemelga G, Yeghiazarians Y Curr Hypertens Rep. 2022; 24(10):445-453.

PMID: 35737199 PMC: 9509305. DOI: 10.1007/s11906-022-01204-6.

Vitamin D and calcium kidney stones: a review and a proposal.

Tavasoli S, Taheri M Int Urol Nephrol. 2018; 51(1):101-111.

PMID: 30136085 DOI: 10.1007/s11255-018-1965-z.

References

Tomaschitz A, Pilz S, Ritz E, Grammer T, Drechsler C, Boehm B . Independent association between 1,25-dihydroxyvitamin D, 25-hydroxyvitamin D and the renin-angiotensin system: The Ludwigshafen Risk and Cardiovascular Health (LURIC) study. Clin Chim Acta. 2010; 411(17-18):1354-60. DOI: 10.1016/j.cca.2010.05.037. View

Li Y, Kong J, Wei M, Chen Z, Liu S, Cao L . 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest. 2002; 110(2):229-38. PMC: 151055. DOI: 10.1172/JCI15219. View

Zhou C, Lu F, Cao K, Xu D, Goltzman D, Miao D . Calcium-independent and 1,25(OH)2D3-dependent regulation of the renin-angiotensin system in 1alpha-hydroxylase knockout mice. Kidney Int. 2008; 74(2):170-9. DOI: 10.1038/ki.2008.101. View

Vaidya A, Sun B, Forman J, Hopkins P, Brown N, Kolatkar N . The Fok1 vitamin D receptor gene polymorphism is associated with plasma renin activity in Caucasians. Clin Endocrinol (Oxf). 2011; 74(6):783-90. PMC: 3089671. DOI: 10.1111/j.1365-2265.2011.03991.x. View

Holick M . Vitamin D deficiency. N Engl J Med. 2007; 357(3):266-81. DOI: 10.1056/NEJMra070553. View

Lambers Heerspink H, Agarwal R, Coyne D, Parving H, Ritz E, Remuzzi G . The selective vitamin D receptor activator for albuminuria lowering (VITAL) study: study design and baseline characteristics. Am J Nephrol. 2009; 30(3):280-6. DOI: 10.1159/000225903. View

Tiosano D, Schwartz Y, Braver Y, Hadash A, Gepstein V, Weisman Y . The renin-angiotensin system, blood pressure, and heart structure in patients with hereditary vitamin D-resistance rickets (HVDRR). J Bone Miner Res. 2011; 26(9):2252-60. DOI: 10.1002/jbmr.431. View

Fishbane S, Chittineni H, Packman M, Dutka P, Ali N, Durie N . Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial. Am J Kidney Dis. 2009; 54(4):647-52. DOI: 10.1053/j.ajkd.2009.04.036. View

Sugden J, Davies J, Witham M, Morris A, Struthers A . Vitamin D improves endothelial function in patients with Type 2 diabetes mellitus and low vitamin D levels. Diabet Med. 2008; 25(3):320-5. DOI: 10.1111/j.1464-5491.2007.02360.x. View

10.

Burgess E, Hawkins R, Watanabe M . Interaction of 1,25-dihydroxyvitamin D and plasma renin activity in high renin essential hypertension. Am J Hypertens. 1990; 3(12 Pt 1):903-5. DOI: 10.1093/ajh/3.12.903. View

11.

Pilz S, Marz W, Wellnitz B, Seelhorst U, Fahrleitner-Pammer A, Dimai H . Association of vitamin D deficiency with heart failure and sudden cardiac death in a large cross-sectional study of patients referred for coronary angiography. J Clin Endocrinol Metab. 2008; 93(10):3927-35. DOI: 10.1210/jc.2008-0784. View

12.

Forman J, Williams J, Fisher N . Plasma 25-hydroxyvitamin D and regulation of the renin-angiotensin system in humans. Hypertension. 2010; 55(5):1283-8. PMC: 3023301. DOI: 10.1161/HYPERTENSIONAHA.109.148619. View

13.

Pilz S, Tomaschitz A, Ritz E, Pieber T . Vitamin D status and arterial hypertension: a systematic review. Nat Rev Cardiol. 2009; 6(10):621-30. DOI: 10.1038/nrcardio.2009.135. View

14.

Resnick L, Muller F, LARAGH J . Calcium-regulating hormones in essential hypertension. Relation to plasma renin activity and sodium metabolism. Ann Intern Med. 1986; 105(5):649-54. DOI: 10.7326/0003-4819-105-5-649. View

15.

Leu M, Giovannucci E . Vitamin D: epidemiology of cardiovascular risks and events. Best Pract Res Clin Endocrinol Metab. 2011; 25(4):633-46. DOI: 10.1016/j.beem.2011.04.001. View

16.

Kobori H, Nangaku M, Navar L, Nishiyama A . The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev. 2007; 59(3):251-87. DOI: 10.1124/pr.59.3.3. View

17.

de Zeeuw D, Agarwal R, Amdahl M, Audhya P, Coyne D, Garimella T . Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet. 2010; 376(9752):1543-51. DOI: 10.1016/S0140-6736(10)61032-X. View

18.

Holick M, Binkley N, Bischoff-Ferrari H, Gordon C, Hanley D, Heaney R . Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011; 96(7):1911-30. DOI: 10.1210/jc.2011-0385. View

19.

Vaidya A, Forman J, Hopkins P, Seely E, Williams J . 25-Hydroxyvitamin D is associated with plasma renin activity and the pressor response to dietary sodium intake in Caucasians. J Renin Angiotensin Aldosterone Syst. 2011; 12(3):311-9. PMC: 3146958. DOI: 10.1177/1470320310391922. View

20.

Freundlich M, Quiroz Y, Zhang Z, Zhang Y, Bravo Y, Weisinger J . Suppression of renin-angiotensin gene expression in the kidney by paricalcitol. Kidney Int. 2008; 74(11):1394-402. DOI: 10.1038/ki.2008.408. View